CMTA Clementia Pharmaceuticals Inc

Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences

Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences

MONTREAL, Sept. 05, 2018 (GLOBE NEWSWIRE) -- (NASDAQ: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the company’s participation at the following upcoming conferences:

American Society for Bone and Mineral Research (ASBMR) 2018

Clementia will present a poster detailing updated data from its Phase 2 clinical trial of palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP) at the ASBMR 2018 Annual Meeting.

Details are as follows:

Abstract Title:  Palovarotene Reduces New Heterotopic Ossification in Fibrodysplasia Ossificans Progressiva (FOP) (Presentation Number:  MON-1066)

Date and Time: Oct. 1, 2018 from 12:00 - 2:00 p.m. ET

Location: ASBMR Discovery Hall – Exhibit Hall 220 B-E

In addition, Clarissa Desjardins, Ph.D., chief executive officer and founder of Clementia, will present at the following investor conferences:

  • The Morgan Stanley Annual Global Healthcare Conference in New York City on Wednesday, Sept. 12, 2018 at 3:40 p.m. ET
  • The Leerink Partners 2018 Rare Disease Roundtable in New York City on Tuesday, Oct. 2, 2018 at 2:00 p.m. ET

Webcasts of the Morgan Stanley and Leerink Partners conference presentations will be available in the Investor Relations section of the company's website at . A replay of each webcast will be available for 30 days following the event.

About Clementia Pharmaceuticals Inc.

Clementia is a clinical-stage company innovating new treatments for people with ultra-rare bone disorders and other diseases with high medical need. The company’s lead product candidate, palovarotene, a novel RARγ agonist, is currently being evaluated in the Phase 3 MOVE Trial to treat fibrodysplasia ossificans progressiva (FOP) and in the Phase 2 MO-Ped Trial to treat multiple osteochondromas (MO, also known as multiple hereditary exostoses/MHE). Clementia is also investigating palovarotene for the potential treatment of other conditions that may benefit from RARγ therapy. For more information, please visit  and connect with us on Twitter @ClementiaPharma.

Investor/Media Contact:

Joseph Walewicz

Clementia Pharmaceuticals Inc.

Chelcie Lister

THRUST Strategic Communications

 

EN
05/09/2018

Underlying

CMTAClementia Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Clementia Pharmaceuticals Inc

 PRESS RELEASE
Free
CMTA Clementia Pharm...

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Appro...

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A. MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in c...

April 11, 2019 1 EN
 PRESS RELEASE
Free
CMTA Clementia Pharm...

Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangemen...

Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A. MONTREAL, April 09, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that its shareholders have approved the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred paym...

April 9, 2019 1 EN
 PRESS RELEASE
Free
CMTA Clementia Pharm...

Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 F...

Clementia Announces Cancellation of Fourth Quarter and Year-End 2018 Financial Results and Conference Call MONTREAL, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the company will not report its fourth quarter and year end 2018 financial results on Feb. 28, 2019, and will cancel the associated conference call and its participation in the 2019 SVB Leerink Global Healthcare Conference. These cancellations are ...

February 26, 2019 1 EN
 PRESS RELEASE
Free
CMTA Clementia Pharm...

Clementia Announces Date of Fourth Quarter and Full Year 2018 Results ...

Clementia Announces Date of Fourth Quarter and Full Year 2018 Results and Presentation at 8th Annual SVB Leerink Global Healthcare Conference MONTREAL, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that management will host a conference call in conjunction with the announcement of its fourth quarter and full-year 2018 financial results and present at the 8th Annual SVB Leerink Partners Healthcare Conference. Detai...

February 20, 2019 1 EN
 PRESS RELEASE
Free
CMTA Clementia Pharm...

Clementia Granted Rare Pediatric Disease Designation by FDA for Palova...

Clementia Granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva MONTREAL, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). Palovarotene, an investigational therapy for FOP, has previousl...

February 11, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch